MAP2K7 and colorectal cancer: The goal of this study was to evaluate the efficacy of the combination of an Aurora A kinase inhibitor and MEK inhibitor in colorectal cancer models, with an early focus on identification of a molecular subgroup of CRC more likely to benefit from such therapy.